EVOKE-SCLC-04 - (GS-US-600-6165)

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04).

Ouvert à Paris depuis le : 24/07/2025
Public cible : Adult
Phase : Phase III

Description de l'essai

To compare the effect of sacituzumab govitecan (SG) to standard of care (SOC) on Objective Response Rate (ORR) as assessed by blinded independent central review (BICR) per RECIST v1.1.;To compare the effect of SG to SOC on Overall Survival (OS).;Primary Endpoints:;ORR: Percentage of participants with complete or partial response per BICR using RECIST v1.1.;OS: Time from randomization to death from any cause

Url of the trial

Investigateur principal

NICOLAS GIRARD

Professeur - Médecin

Contacter